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e-mail address: idr_alfawaz@yahoo.comAbdullah M. Alfawaz ⇑AbstractWegener’s granulomatosis is a granulomatous disorder associated with systemic necrotizing vasculitis. Eye involvement occurs in
approximately 50% of Wegener’s granulomatosis patients and is an important cause of morbidity. Conventional treatment-related
morbidity and failure have led to studies of alternative treatment modalities. In this case of a 35-year-old man with severe Wege-
ner’s granulomatosis, conventional therapy failed to induce remission. Despite the standard immunosuppressive therapy, progres-
sion of the disease was observed, mainly with ocular manifestations and renal impairment. Rituximab was given intravenously and
led to remission of both systemic and ocular manifestations of the disease. After 1 year of disease quiescence, he was admitted
one week after his third regularly-scheduled rituximab treatment and was started on intravenous methylprednisolone, 500 mg/day
for 3 days, before cataract surgery. Subsequently, the patient underwent phacoemulsification cataract surgery in his left eye. Six
months later, in the same manner he underwent uneventful phacoemulsification cataract surgery in the right eye with a favorable
outcome in both eyes. Conclusion: In this patient, rituximab was a well-tolerated and effective remission induction agent for severe
refractory Wegener’s granulomatosis and led to successful cataract surgery.
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Wegener’s granulomatosis (WG) is a primary systemic
small-vessel vasculitis with eye, respiratory tract, and kidney
involvement.1 B lymphocytes are important for the regulation
of immune responses and production of antibodies. B cells
function as antigen-presenting cells, express costimulatory
molecules, produce cytokines, and regulate the differentia-
tion and activation of T lymphocytes. The role of B cells in
the pathogenesis of autoimmune diseases including WG is
well-established.2 Rituximab is a chimeric monoclonal anti-
body directed against CD20, a cell surface protein expressedalmost exclusively on B cells.3 Binding of rituximab to CD20
results in the selective depletion of B cells by a variety of
mechanisms.4 Hence, rituximab has become an important
component of standard treatment regimens for non-
Hodgkin’s B-cell lymphoma.5 Because B cells play an impor-
tant role in autoimmune diseases,6 rituximab is increasingly
being investigated as a therapeutic agent for these indica-
tions. Early reports of its successful use in autoantibody-
mediated autoimmune diseases were followed by promising
results in multisystem autoimmune diseases such as rheuma-
toid arthritis. In a report of 10 patients with ocular and
orbital WG, the authors found that intravenous infusions ofe:
al.com
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In the present case report of an individual with ocular and
generalized WG who failed conventional treatment, adminis-
tration of rituximab led to a complete control of the disease.Figure 1. A and B: Preoperative photographs of the left eye with scleral
thinning, posterior synechiae and cataract.
Figure 2. Postoperative photograph of the right eye showing quit eye
with intraocular lens.Case report
A 35-year-old man presented with complaints of poor
vision in his right eye for the previous eight months. His eye
symptoms started with a gradual painless reduction of vision
for which he was seen at another institute and diagnosed as
having a choroidal mass for investigations. When he came to
our hospital his best-corrected visual acuity was 20/200 in the
right eye and 20/60 in the left eye. Intraocular pressure (IOP)
was 17 mmhg in each eye and generalized scleral thinning
was occurring in both eyes without inflammation or active
necrosis. Conjunctiva was normal in both eyes, the anterior
chamber showed 1+ cells and 1+ flare in both eyes, and there
was 360 posterior synechia in the right eye. The patient had
a dense white cataract in the right eye with no view to the
retina and an immature posterior subcapsular cataract in
the left eye. Fundus examination of the left eye showed a nor-
mal optic nerve and mild choroidal folds. Ultrasonography of
the right eye showed mild macular elevation but was other-
wise normal. Laboratory studies showed high plasma levels
of urea and creatinine (14.2 mmol/L and 156 lmol/L respec-
tively) and the presence of circulating cytoplasmic anti-
neutrophilic cytoplasmic antibodies (c-ANCAs).
The patient was admitted to complete his workup. During
hospitalization he was diagnosed with WG, renal failure, and
eye involvement. A kidney biopsy revealed necrotizing and
crescentic glomerulonephritis. A lung biopsy confirmed the
diagnosis by showing granulomatous inflammation with
extensive necrosis and vasculitis. The patient was started on
oral prednisolone 50 mg (0.75 mg/kg) and cyclophos-
phamide 100 mg (1.5 mg/kg) once-daily. After 1 month of
treatment, no improvement was observed. The patient was
then treated with rituximab (MabThera; Hoffmann-La Roche,
Basel, Switzerland) in 2 intravenous doses of 1 g each, given
2 weeks apart and repeated at 6 month intervals, supple-
mented with daily oral prednisolone 10 mg. After initiation
of this treatment regimen, the patient exhibited complete
resolution of his symptoms and WG was in clinical remission.
After complete remission for one year, the patient
reported poor vision in both eyes. His visual acuity in the right
eye was counting finger near face and 20/200 in the left eye.
Slit-lamp examination revealed quiet eyes and IOP was
14 mm Hg in each eye. There was no view to the fundus in
the right eye, and the left eye showed a normal optic nerve
and an early epiretinal membrane (Fig. 1A and B). The patient
was admitted one week after his third regularly-scheduled
rituximab treatment and was started on intravenous methyl-
prednisolone, 500 mg/day for 3 days (half the usual dose
given in uveitis patents because of his kidney status) before
cataract surgery. On the second day, he underwent release
of posterior synechiae, phacoemulsification with clear corneal
incision, and implantation of posterior chamber intraocular
lens in the left eye. On the first day postoperatively, the
patient’s visual acuity in the left eye improved to 20/60 with
no activation of scleritis or uveitis. The vision did not improve
completely because of macular dragging and a thick epireti-
nal membrane. Six months later immediately after his forthdose, the patient underwent uneventful phacoemulsification
cataract surgery in the right eye with coverage by intravenous
methylprednisolone, 500 mg/day for 3 doses. Six months
after the second eye surgery his best-corrected visual
acuity was 20/60 in the right eye and 20/30 in the left eye,
after being on rituximab infusion every 6 months and azathio-
prine (imuran) 25 mg daily (Fig. 2). Based on the quiescence
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able to stop rituximab infusions and was maintained on
5 mg oral steroid without any exacerbation of disease for
eight months.Discussion
This is a case of a male patient with a severe form of
WG who had impairment of vision secondary to cataract
and choroidal granuloma and responded well to systemic
rituximab infusion. One long-term study of WG patients
found that 52% of them developed ophthalmologic dis-
ease, and 8% of the patients had disease-related vision
loss.8 WG may affect any part of the eye and WG-related
eye pathologies frequently manifest as a component of a
multisystem presentation.9 They often occur secondary to
contiguous granulomatous sinus or nasal disease, and
patients may present with proptosis, obstruction of the
nasolacrimal duct, ocular muscle involvement, or optic
neuropathy. In a study of 140 WG patients, Bullen and
colleagues noted ocular disease in 29% of cases (40/140).
Orbital disease was the most common manifestation
(18/140, 15%), followed by scleral (7%) and episcleral
(3.5%) involvement.10
It is crucial to recognize that any signs of ocular inflamma-
tion in a patient with WG may indicate active disease in other
organs. Therefore, thorough clinical and laboratory examina-
tions should be performed to determine the extent of the
disease.9
Patients with WG can initially present with various ophthal-
mologic manifestations. Hoffman et al. reported scleritis as
the most common presenting ophthalmologic manifestation,
occurring in approximately 10% of WG patients.8 The oph-
thalmologist may make an initial diagnosis of WG in patients
who present with ocular complaints or patients who have
undiagnosed systemic involvement in addition to their ocular
disease.11 In our patient, the ocular manifestations were the
presenting complaints which preceded the systemic manifes-
tations by several months. Retinal and choroidal involve-
ments in WG seem to be rare.8 In Bullen’s study, 2.9% of
patients had retinitis and one had a branch venous obstruc-
tion.9 Sclero-choroidal granulomas may mimic the appear-
ance of a uveal melanoma.12 Choroidal folds, choroidal
effusions, or an exudative retinal detachment may be seen
in association with chorioretinal granulomas or posterior scle-
ritis.9 Our patient initially presented to ophthalmic emer-
gency and was found to have a choroidal mass, thought to
be choroidal melanoma, in his right eye. Subsequently he
had bouts of bilateral low-grade anterior uveitis, which was
managed with topical anti-inflammatory medications. Uveitis
is an uncommon manifestation in WG patients. It was the
least common form of ocular involvement in patients with
WG in Bullen’s study (4/140, 2.9%).10 Anterior, posterior, or
pan-uveitis may be present in WG patients. Rarely, uveitis
may be the initial manifestation, followed by active inflamma-
tion in surrounding structures.13
Other important systemic features in WG patients include
pyrexia, weight loss, recurrent epistaxis, sinus discharge,
hemoptysis, peripheral neuropathy, cerebral vasculitis, and
renal failure (the major cause of death). Our patient had sev-
ere renal impairment which was irreversible even after the ini-
tiation of rituximab treatment. His treatment course suggeststhat the early use of rituximab in patients with severe WG is
recommended to prevent irreversible systemic and ocular
damage.14
Cataract development in WG patients is reported to be as
common as 28%.15 Its causes include uveitis and use of topi-
cal or systemic steroids. Literatures are lacking for studies
discussing cataract surgery in WG patients and its outcome.
Successful treatment of ocular involvement or complications
of WG are dependent on treatment of the underlying disease
with systemic immunomodulators. Precautions should be
taken to achieve favorable outcomes after cataract
surgery. These precautions should include quiescence of ocu-
lar inflammation for a period of at least three months before
surgery. In addition, one may use periocular steroids immedi-
ately before and after surgery. Avoiding scleral manipulation
is important to prevent activating scleral inflammation. Clear
corneal incision phacoemulsification is a better option than
extracapsular cataract extraction. In our patient all of these
measures were taken, plus timing the surgery to be within
one week of rituximab infusion. It seems that all of these
factors led to a favorable outcome in both eyes without
exacerbation of the disease.
In conclusion, this case showed that intravenous infusions
of rituximab can induce long-term remission in refractory
ophthalmic WG. Rituximab-mediated clinical remission
allows for safe and successful surgical intervention.Declaration of interest
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